SRMS as a Novel Therapeutic Target in Gastric Cancer Peritoneal Metastases by Quintanilla, Jaqueline et al.
Introduction
Affecting over 1 million people in the past 
year, gastric adenocarcinoma (GAC) is the 
5th most common cancer in the population 
and the 4th most common cause of cancer 
fatalities.1 GAC with peritoneal 
carcinomatosis (PC) is common affecting 
~45% of patients during the course of GAC 
and leads to poor survival, but the molecular 
events leading to PC are not clear.2 Our 
recent RNAseq of PC specimen revealed 
that SRMS (Src-related kinase lacking C-
terminal regulatory tyrosine and N-terminal 
myristylation sites), a nonreceptor tyrosine 
kinase, was amplified in PC samples and 
highly upregulated in the diffuse type and 
signet-ring cell (SRC) subtypes of GAC with 
especially poor prognosis. We aim to 
elucidate its function and whether it could be 
a therapeutic target in GAC with PC. 
Discussion
• TCGA data and western blot images 
show that patient-derived PC cells, such 
as GA0518 and GA0804, have higher 
expression of SRMS than primary tumor 
cells and normal gastric cells (Figure 1 
and 2)
• Inhibitor HJC0378 (C22H24CIN3O4S) was 
able to suppress SRMS and other 
oncoproteins’ expression in GA0518 cells 
(highest expressing SRMS cells) (Figure 
4 and 5)
• Both HJC0378 and Dasatinib were able 
to significantly suppress tumor cell 
growth and invasive capacity (Figure 6)
• pCMV3.1-SRMS overexpression 
transfection in AGS cells (lowest 
expressing SRMS cells), increased the 
expression of several other genes 
including SOX9 and YAP1, which’s 
protein were previously inhibited 
alongside SRMS by inhibitors HJC0378 
and Dasatinib (Figure 3-5)
• There is a correlation between some 
oncoproteins’ increase in expression, 
such as TRIM28, YAP1, phosphor-
STAT3, and phosphor-S6, alongside 
SRMS’ overexpression (Figure 3)
Conclusion
• SRMS is overexpressed in patient-
derived metastatic PC cells compared to 
normal gastric cells or primary gastric 
cancer cells. 
• Overexpression of SRMS in GAC cells 
increased YAP1/TAZ and SOX9 
oncoproteins and also increased p-
STAT3 and phospho-S6, a marker for 
mTOR activation suggesting the role of 
SRMS in tumor progression. 
• SRC inhibitor Dasatinib can suppress 
SRMS and other oncoproteins and 
significantly suppress GAC tumor cell 
invasion.
• Most importantly, we discovered a novel 
inhibitor HJC0378 (C22H24CIN3O4S) that 
has proven to be a more effective SRMS 
inhibitor.
• Thus, SRMS is a potential novel target in 
GAC with PC.
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Fig. 2 Overexpression of SRMS in patient-derived metastatic PC cells is 
much higher than normal and other cells. Western blot identifying 
expression of SRMS in various cell lines (GES-1: Gastric Epithelial Cells; 
N87-SNU16: Primary Gastric Cancer Cells; GA0518-GA0825: Patient-
derived PC cells; 102616-0816F: Cancer-Associated Fibroblasts)
Methods
Western blot and real-time polymerase 
chain reaction (qPCR) were used to 
determine the expression of SRMS in GAC 
cell lines and tissues. Transfection of SRMS 
cDNA in AGS cells utilized the jetPRIME® 
protocol to study the function and signaling 
activated by SRMS. GA0518 patient-derived 
PC cells, AGS GAC cells and Flo-1 radiation 
resistant XTR cells were used to study the 
functions of SRMS including proliferation, 
invasion, and tumor sphere forming capacity 
in vitro. Dasatinib, an inhibitor of SRC, being 
reported to suppress SRMS and a novel 
inhibitor HJC0378 were tested for their 
suppression of SRMS and other oncogenic 
signaling as well as on inhibition of tumor 
cell malignant phenotypes. 
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Fig. 1 SRMS was highly expressed in GAC tumor tissues 
compared to normal and adjacent normal (A: TCGAA) and highly 
expressed in metastatic PC samples by RNAseq (B)
Fig. 6 Dasatinib and HJC0378 significantly inhibit four 
tumor cell invasion. A. Invasion of GAC cells was 
reduced when four GAC cells (1) AGS 2) GA0518 3) 
FLO-1 4) FLO-1 XTR) were treated with 12.5 and 25 
nM of Dasatinib and HJC0378 respectively; B. 









































Ability of SRMS Inhibitors to 
Reduce Tumor Growth and 










































































































































SRMS Expression in GAC
Fig. 5 GA0518’s (highest expressing SRMS cell line) expression of 
some proteins, such as TAZ and TRIM28, were significantly reduced 
when treated with three concentrations (12.5, 25, and 50 nM) of SRMS 










































































































































Fig. 4 HJC0378, a P-STAT3 inhibitor, demonstrates to be more 
effective than Dasatinib in inhibiting SRMS and other important proteins, 


















































Fig. 3 A. Overexpression of SRMS in AGS cells by transfection 
of SRMS cDNA (pcDNA3.1SRMS) in AGS cells increased SRMS and 
SOX9, YAP1, BIRC5 oncogene expression and B. phospho-Stat3, 
phospho-S6 in AGS cells indicating SRMS activate these oncogenic 
signaling in GAC cells
A. 
B. 
A
G
S
G
A
0
5
1
8
F
L
O
-1
F
L
O
-1
 X
T
R
A. 
B.
